References
- Frenning G. Modelling drug release from inert matrix systems: from moving-boundary to continuous-field descriptions. Int J Pharm 2011;418:88–99
- Bonferoni MC, Rossi S, Ferrari F, et al. On the employment of λ carrageenan in a matrix system. III. Optimization of a λ carrageenan–HPMC hydrophilic matrix. J Control Release 1998;51:231–239
- Gupta VK, Hariharan M, Wheatley TA, Price JC. Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors. Eur J Pharm Biopharm 2001;51:241–242
- Nerurkar J, Jun HW, Price JC, Park MO. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates. Eur J Pharm Biopharm 2005;61:56–68
- Bonferoni MC, Rossi S, Ferrari F, Caramella C. Development of oral controlled release tablet formulations based on diltiazem-carrageenan complex. Pharm Dev Technol 2004;9:155–162
- Harikaran M, Wheatley TA, Price JC. Controlled release tablet matrices from carrageenans: compression and dissolution studies. Pharm Dev Technol 1997;2:383–393
- Dorożyński P, Kulinowski P, Mendyk A, Jachowicz R. Gastroretentive drug delivery systems with L-dopa based on carrageenans and hydroxypropylmethylcellulose. Int J Pharm 2011;404:169–170
- Carrageenan. How a “natural” food additive is making us sick. A Report by the Cornucopia Institute, March 2013:1--34
- Pavli M, Vrečer F, Baumgartner S. Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate. Int J Pharm 2010;400:15–16
- Kranz H, Jürgens K, Pinier M, Siepmann J. Drug release from MCC- and carrageenan-based pellets: experiment and theory. Eur J Pharm Biopharm 2009;73:302–303
- Kagan L, Lapidot N, Afargan M, et al. Gastroretentive accordion pill: enhancement of riboflavin bioavailability in humans. J Control Release 2006;113:208–215
- Jusko WJ, Levy G. Absorption, metabolism, and excretion of riboflavin-5′-phosphate in man. J Pharm Sci 1967;56:58–62
- Mahalingam R, Jasti B, Birudaraj R, et al. Evaluation of polyethylene oxide compacts as gastroretentive delivery systems. AAPS PharmSciTech 2009;10:98–103
- Murphy C, Pillay V, Choonara YE, et al. Optimization of a dual mechanism gastrofloatable and gastroadhesive delivery system for narrow absorption window drugs. AAPS PharmSciTech. 2012;13:1–14
- European Pharmacopoeia, 4th ed. Strasbourg Cedex, France: Council of Europe; 2001
- Cavinato M, Bresciani M, Machin M, et al. Formulation design for optimal high-shear wet granulation using on-line torque measurements. Int J Pharm 2010;38:48–55
- Chitu TM, Oulahna D, Hemati M. Wet granulation in laboratory scale high shear mixers: effect of binder properties. Powder Technol 2011;206:25–33
- Levin M. Wet granulation: end-point determination and scale-up. Available from: http://www.mcc-online.com/granulation.htm [last accessed 14 April 2014]
- Gohel MC, Jogani PD, Bariya SE. Development of agglomerated directly compressible diluent consisting of brittle and ductile materials. Pharm Dev Technol 2003;8:143–151